Revolution Medicines, Inc. (NASDAQ:RVMDW) Short Interest Update

Revolution Medicines, Inc. (NASDAQ:RVMDW) was the target of a large decline in short interest in July. As of July 31st, there was short interest totaling 1,153 shares, a decline of 47.6% from the July 15th total of 2,202 shares. Based on an average trading volume of 16,349 shares, the days-to-cover ratio is presently 0.1 days.

Revolution Medicines Price Performance

Shares of RVMDW remained flat at $11.10 during midday trading on Friday. The company’s stock had a trading volume of 11,973 shares, compared to its average volume of 116,662. The firm has a fifty day moving average of $8.79 and a 200 day moving average of $5.19. Revolution Medicines has a 1 year low of $0.16 and a 1 year high of $11.67.

Revolution Medicines Company Profile

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.